Hester Bios
NSE: HESTERBIO · Pharmaceuticals
Snapshot
Unlock Hester Bios's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hester Biosciences Limited is an Indian pharmaceutical company specialising in the manufacturing and distribution of veterinary vaccines and animal health products. Its operations are divided into poultry healthcare and animal healthcare segments, providing a comprehensive range of vaccines, feed supplements, and herbal health solutions.
Business Model
The company generates revenue through the production and sale of biologicals and health products for poultry and large animals. It serves both domestic and international markets by providing essential disease prevention and nutritional support for livestock.
Growth Outlook
Growth is driven by the expansion of its vaccine portfolio for large animals and the increasing demand for herbal health supplements in the veterinary sector. The company continues to focus on enhancing its product range to address diverse infectious diseases in livestock.
Key Risks
- Disease Outbreak Volatility. The demand for veterinary vaccines is highly dependent on the unpredictable occurrence and severity of animal disease outbreaks.
- Regulatory Compliance. The company faces stringent regulatory requirements for manufacturing biological products, which can impact production timelines and costs.
- Raw Material Price Fluctuations. Volatility in the costs of raw materials and active pharmaceutical ingredients can adversely affect profit margins.
- Export Market Risks. Operating internationally exposes the company to geopolitical instability, currency fluctuations, and varying import regulations in different countries.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Hester Bios and 5,000+ companies — free.
Key Metrics
REVENUE
₹333 Cr
TTM · consolidated
NET PROFIT
₹57 Cr
TTM · consolidated
EPS
₹67.57
TTM · consolidated
RETURN ON EQUITY
17.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.2%
TTM · consolidated
P/E
36.1x
Q4 FY26 · consolidated
EV/EBITDA
23.5x
Q4 FY26 · consolidated
EBITDA MARGIN
29.0%
TTM · consolidated
NET PROFIT MARGIN
16.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
Ind-Swift Labs.INDSWFTLAB | 1,168 | 44.47 | 17.62 | 226.0% | 14.7% | 3.4% | 4.0% | +121.7% |
Venus RemediesVENUSREM | 1,157 | 23.25 | 14.80 | 18.0% | 20.9% | 17.5% | 22.1% | +239.7% |
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
Beta Drugs LtdBETA | 1,096 | — | — | — | 20.0% | — | — | +34.8% |
As of Q4 FY26
Financials
Hester Bios
NSE: HESTERBIO · Pharmaceuticals
Snapshot
Unlock Hester Bios's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hester Biosciences Limited is an Indian pharmaceutical company specialising in the manufacturing and distribution of veterinary vaccines and animal health products. Its operations are divided into poultry healthcare and animal healthcare segments, providing a comprehensive range of vaccines, feed supplements, and herbal health solutions.
Business Model
The company generates revenue through the production and sale of biologicals and health products for poultry and large animals. It serves both domestic and international markets by providing essential disease prevention and nutritional support for livestock.
Growth Outlook
Growth is driven by the expansion of its vaccine portfolio for large animals and the increasing demand for herbal health supplements in the veterinary sector. The company continues to focus on enhancing its product range to address diverse infectious diseases in livestock.
Key Risks
- Disease Outbreak Volatility. The demand for veterinary vaccines is highly dependent on the unpredictable occurrence and severity of animal disease outbreaks.
- Regulatory Compliance. The company faces stringent regulatory requirements for manufacturing biological products, which can impact production timelines and costs.
- Raw Material Price Fluctuations. Volatility in the costs of raw materials and active pharmaceutical ingredients can adversely affect profit margins.
- Export Market Risks. Operating internationally exposes the company to geopolitical instability, currency fluctuations, and varying import regulations in different countries.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Hester Bios and 5,000+ companies — free.
Key Metrics
REVENUE
₹333 Cr
TTM · consolidated
NET PROFIT
₹57 Cr
TTM · consolidated
EPS
₹67.57
TTM · consolidated
RETURN ON EQUITY
17.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.2%
TTM · consolidated
P/E
36.1x
Q4 FY26 · consolidated
EV/EBITDA
23.5x
Q4 FY26 · consolidated
EBITDA MARGIN
29.0%
TTM · consolidated
NET PROFIT MARGIN
16.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26